FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2157547590> ?p ?o ?g. }

• W2157547590 endingPage "195" @default.
• W2157547590 startingPage "183" @default.
• W2157547590 abstract "ABSTRACT Introduction: The safety and tolerability profiles of antidepressants can often influence the treatment choices of clinicians treating major depressive disorder. The purpose of this investigation was to characterize the safety and tolerability of desvenlafaxine (administered as desvenlafaxine succinate) in treating depression. Methods: An integrated analysis of all short-term, randomized, double-blind, placebo-controlled registration studies for major depressive disorder (four flexible-dose and five fixed-dose studies) was performed. Adult outpatients with major depressive disorder received desvenla-faxine doses ranging from 50–400 mg/day or placebo for 8 weeks. Treatment-emergent adverse events, laboratory values, vital signs, and discontinuation symptoms were evaluated. In the subset of fixed-dose studies, dose-related effects were analyzed. Results: In the overall population (placebo: n=1,116; desvenlafaxine: n=1,834), adverse events resulted in discontinuations in 3% of placebo-treated patients and 12% of desvenla-faxine-treated patients; in the subset of fixed-dose studies, the rates were 4% with placebo and increased with desvenlafaxine dose (50 mg/ day: 4%; 400 mg/day: 18%). The most common treatment-emergent adverse event was transient nausea that was generally mild to moderate. The most common sexual dysfunction associated with desvenlafaxine treatment was erectile dysfunction in men (7% vs 1% with placebo) and anorgasmia in women (1% and 0%). One desvenlafaxine-treated patient died of a completed suicide; there were four suicide attempts (three desvenlafaxine, one placebo) and eight cases of suicidal ideation (five desvenlafaxine, three placebo) during the on-therapy period. Small but statistically significant changes in mean blood pressure occurred at all desvenlafaxine doses; clinically meaningful changes were observed in 1% of placebo-treated patients and 2% of desvenlafaxine-treated patients. Desvenlafaxine was associated with small but statistically significant mean changes in laboratory assessments, particularly lipid and liver enzyme elevations, and electrocardiograms; few cases of these changes were clinically relevant. Conclusion: Desvenlafaxine in the treatment of major depressive disorder exhibited a safety and tolerability profile generally consistent with the serotonin-norepinephrine reuptake inhibitor class. The most common adverse event was transient nausea. At the recommended therapeutic dose of 50 mg/day, discontinuation due to adverse events was similar to placebo." @default.
• W2157547590 created "2016-06-24" @default.
• W2157547590 creator A5017307477 @default.
• W2157547590 creator A5020995037 @default.
• W2157547590 creator A5042407610 @default.
• W2157547590 creator A5048776340 @default.
• W2157547590 creator A5068545843 @default.
• W2157547590 date "2009-04-01" @default.
• W2157547590 modified "2023-09-23" @default.
• W2157547590 title "An Integrated Analysis of the Safety and Tolerability of Desvenlafaxine Compared with Placebo in the Treatment of Major Depressive Disorder" @default.
• W2157547590 cites W1964022439 @default.
• W2157547590 cites W1969712323 @default.
• W2157547590 cites W1979796529 @default.
• W2157547590 cites W2022191212 @default.
• W2157547590 cites W2027112615 @default.
• W2157547590 cites W2041082027 @default.
• W2157547590 cites W2043410495 @default.
• W2157547590 cites W2044018276 @default.
• W2157547590 cites W2059641466 @default.
• W2157547590 cites W2074133854 @default.
• W2157547590 cites W2078627160 @default.
• W2157547590 cites W2084168719 @default.
• W2157547590 cites W2114613490 @default.
• W2157547590 cites W2115031069 @default.
• W2157547590 cites W2131823335 @default.
• W2157547590 cites W2144767826 @default.
• W2157547590 cites W2171466849 @default.
• W2157547590 cites W2418300191 @default.
• W2157547590 doi "https://doi.org/10.1017/s1092852900020204" @default.
• W2157547590 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19407730" @default.
• W2157547590 hasPublicationYear "2009" @default.
• W2157547590 type Work @default.
• W2157547590 sameAs 2157547590 @default.
• W2157547590 citedByCount "55" @default.
• W2157547590 countsByYear W21575475902012 @default.
• W2157547590 countsByYear W21575475902013 @default.
• W2157547590 countsByYear W21575475902014 @default.
• W2157547590 countsByYear W21575475902015 @default.
• W2157547590 countsByYear W21575475902016 @default.
• W2157547590 countsByYear W21575475902017 @default.
• W2157547590 countsByYear W21575475902018 @default.
• W2157547590 countsByYear W21575475902019 @default.
• W2157547590 countsByYear W21575475902020 @default.
• W2157547590 countsByYear W21575475902022 @default.
• W2157547590 countsByYear W21575475902023 @default.
• W2157547590 crossrefType "journal-article" @default.
• W2157547590 hasAuthorship W2157547590A5017307477 @default.
• W2157547590 hasAuthorship W2157547590A5020995037 @default.
• W2157547590 hasAuthorship W2157547590A5042407610 @default.
• W2157547590 hasAuthorship W2157547590A5048776340 @default.
• W2157547590 hasAuthorship W2157547590A5068545843 @default.
• W2157547590 hasConcept C118552586 @default.
• W2157547590 hasConcept C126322002 @default.
• W2157547590 hasConcept C142724271 @default.
• W2157547590 hasConcept C197934379 @default.
• W2157547590 hasConcept C204787440 @default.
• W2157547590 hasConcept C27081682 @default.
• W2157547590 hasConcept C2778375690 @default.
• W2157547590 hasConcept C2778715236 @default.
• W2157547590 hasConcept C2779144063 @default.
• W2157547590 hasConcept C2780051608 @default.
• W2157547590 hasConcept C2780580376 @default.
• W2157547590 hasConcept C2908647359 @default.
• W2157547590 hasConcept C71924100 @default.
• W2157547590 hasConcept C99454951 @default.
• W2157547590 hasConceptScore W2157547590C118552586 @default.
• W2157547590 hasConceptScore W2157547590C126322002 @default.
• W2157547590 hasConceptScore W2157547590C142724271 @default.
• W2157547590 hasConceptScore W2157547590C197934379 @default.
• W2157547590 hasConceptScore W2157547590C204787440 @default.
• W2157547590 hasConceptScore W2157547590C27081682 @default.
• W2157547590 hasConceptScore W2157547590C2778375690 @default.
• W2157547590 hasConceptScore W2157547590C2778715236 @default.
• W2157547590 hasConceptScore W2157547590C2779144063 @default.
• W2157547590 hasConceptScore W2157547590C2780051608 @default.
• W2157547590 hasConceptScore W2157547590C2780580376 @default.
• W2157547590 hasConceptScore W2157547590C2908647359 @default.
• W2157547590 hasConceptScore W2157547590C71924100 @default.
• W2157547590 hasConceptScore W2157547590C99454951 @default.
• W2157547590 hasIssue "4" @default.
• W2157547590 hasLocation W21575475901 @default.
• W2157547590 hasLocation W21575475902 @default.
• W2157547590 hasOpenAccess W2157547590 @default.
• W2157547590 hasPrimaryLocation W21575475901 @default.
• W2157547590 hasRelatedWork W1966047811 @default.
• W2157547590 hasRelatedWork W2003042623 @default.
• W2157547590 hasRelatedWork W2022556905 @default.
• W2157547590 hasRelatedWork W202460821 @default.
• W2157547590 hasRelatedWork W2089245388 @default.
• W2157547590 hasRelatedWork W2147606462 @default.
• W2157547590 hasRelatedWork W2896659597 @default.
• W2157547590 hasRelatedWork W2996750011 @default.
• W2157547590 hasRelatedWork W4251165208 @default.
• W2157547590 hasRelatedWork W2183331092 @default.
• W2157547590 hasVolume "14" @default.
• W2157547590 isParatext "false" @default.
• W2157547590 isRetracted "false" @default.
• W2157547590 magId "2157547590" @default.

• next